Dimension scores are derived from public data and fields; weighted into the composite. Reference only.
Cresco Pharma / Cresco Regulatory Standards FZ-LLC is a consulting service provider focused on regulatory compliance for pharmaceuticals and medical devices. According to its website, it is owned and managed by Cresco Regulatory Standards FZ, L.L.C. and governed by UAE law. It is not positioned as a typical SaaS or enterprise software product, but rather as a market access and compliance consulting firm for medical device manufacturers, traders, healthcare providers, and entrepreneurs.
Its services focus on quality management system implementation, covering FDA 21 CFR 820, ISO 13485:2016, and ISO 9001:2015; quality system gap analysis; quality management training; second-party audits; support for U.S. FDA Premarket Notification / Premarket Approval; preparation of technical documentation under EU MDR 2017/745; and compliance training related to risk management, post-market surveillance, UDI, medical device reporting, and CAPA. It also offers turnkey solutions for setting up medical device or pharmaceutical manufacturing facilities, investor introductions, new product commercialization, and R&D consulting.
The website discloses prices for some services: quality management system services at USD 10,200, FDA premarket notification/approval support at USD 8,500, EU MDR-related services at USD 40,200, and turnkey solutions for setting up healthcare and pharmaceutical industry facilities at USD 80,900. All prices still require contact for a customized quote. Payment methods include wire transfer, secure online payment, Amazon Pay, Visa, and MasterCard, with prices denominated in USD. Refunds are only available if the service has not yet started or no service contract has been signed.
The advantages are that its service scope is relatively clear, covering the U.S., EU, and relevant Middle Eastern markets, with explicit emphasis on project plans, timelines, milestones, confidentiality, and compliant execution. Compared with many consulting firms, its publicly listed reference pricing also helps clients make an initial budget assessment. The drawbacks are that it is not a SaaS product and does not provide information about an online platform, automated workflows, permission management, third-party integrations, APIs, or cloud/self-hosted deployment. Customer cases, consultant qualifications, and delivery SLAs are also not shown in the main content.
It is best suited for medical device or pharmaceutical companies preparing to enter markets such as the United States, Canada, the EU, KSA, UAE, Qatar, and Oman, especially teams that need support with quality systems, technical documentation, and market access. Access from China is not stated in the main content, so it is considered unknown.
⚠ This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on crescopharma.com official site.
crescopharma.com is an India SaaS provider. TG4G tracks its product information, an overall rating of 4.0/10, and a China-accessibility score of Workable. Click "Visit Official Site" to reach crescopharma.com directly.